Jemperli (dostarlimab-gxly) / AnaptysBio, GSK  >>  Phase 2
Welcome,         Profile    Billing    Logout  

60 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jemperli (dostarlimab-gxly) / GSK
2017-003353-41: Mesothelioma Stratified Therapy (MiST) - Including the following treatment arms: MiST 1 rucaparibMiST 2 abemaciclibMiST 3 pembrolizumab in combination with bemcentinibMiST 4 atezolizumab in combination with bevacizumabMiST 5 dostarlimab in combination with niraparib

Not yet recruiting
2
120
Europe
rucaparib, abemaciclib, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), Pembrolizumab, bemcentinib, KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib, Dostarlimab, CO-338, LY2835219, R05541267/F03, RO4876646/F01, RO4876646/F02, MK-3475, BGB324, Tablet, Capsule, hard, Concentrate for solution for infusion, Solution for infusion, Capsule, Tecentriq, Avastin (for the 100mg/4ml presentation), Avastin (for 400 mg/16 ml presentation), KEYTRUDA (Pembrolizumab, MK3475), KEYTRUDA (pembrolizumab, MK3475), Niraparib
University of Leicester, The British Lung Foundation, Clovis Pharmaceuticals Inc., Eli Lilly & Company, Roche Pharma AG, Merck Sharp & Dohme Limited, BerGenBio ASA, GlaxoSmithKline Research & Development Limited
Malignant Mesothelioma (MM) - pleural and peritoneal, Mesothelioma is a universally lethal cancer caused by Asbestos. There has only been one licenced therapy since 2003. Accordingly there is a pressing need for effective therapy in the relapsed setting, Diseases [C] - Cancer [C04]
 
 
2016-004368-21: Phase II study on clear cells sarcoma Studio sul sarcoma a cellule chiare in fase avanzata

Not yet recruiting
2
21
Europe
Dostarlimab, [TSR-042], Solution for infusion
ITALIAN SARCOMA GROUP, GSK-TESARP
Advanced clear cells sarcoma Sarcoma a cellule chiare in fase avanzata, Advanced clear cells sarcoma Sarcoma a cellule chiare in fase avanzata, Diseases [C] - Cancer [C04]
 
 
2020-000109-10: A Phase II, Open-Label, Single Arm, prospective, multicenter study of niraparib plus dostarlimab in patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germline or somatic mutations in the DNA repair genes Studio prospettico, multicentrico, di fase II, a braccio singolo, sulla combinazione Niraparib+Dostarlimab in pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA

Ongoing
2
70
Europe
niraparib, DOSTARLIMAB, [MK-4827], [TSR-042], Capsule, hard, Solution for injection, ZEJULA, DOSTARLIMAB
DIPARTIMENTO DI ONCOLOGIA-UNIVERSITA' DEGLI STUDI DI TORINO, GSK
patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA, patients with advanced non-small cell lung cancer and malignant pleural mesothelioma, positive for PD-L1 expression and germ or somatic mutations in DNA damage repair genes pazienti con carcinoma polmonare non a piccole cellule avanzato e mesotelioma pleurico maligno, positivo per espressione di PD-L1 e mutazioni germinali o somatiche nei geni di riparo del danno al DNA, Diseases [C] - Cancer [C04]
 
 
2020-002766-14: Combination of Niraparib and Dostarlimab in patients with DNA repair-deficient or platinum-sensitive solid tumors

Not yet recruiting
2
800
Europe
Niraparib, Dostarlimab, TSR-042, Capsule, Solution for infusion
Gustave Roussy, GSK/Tesaro
Patients with DNA repair-deficient or platinum-sensitive solid tumors, Solid tumors, Diseases [C] - Cancer [C04]
 
 
2019-004875-38: The induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Trattamento di induzione e mantenimento con inibitore di PARP e immunoterapia nel carcinoma a cellule squamose della testa e del collo (HNSCC) HPV-negativo

Ongoing
2
49
Europe
niraparib, dostarlimab, [niraparib], [TSR-042 (also known as GSK4057190) and WBP-285], Capsule, hard, Solution for infusion, Zejula
Fondazione GONO, GLAXOSMITHKLINE LLC
HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Carcinoma a cellule squamose della testa e del collo (HNSCC) HPV-negativo, HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC) Carcinoma a cellule squamose della testa e del collo (HNSCC) HPV-negativo, Diseases [C] - Cancer [C04]
 
 
NCT03016338: Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Active, not recruiting
2
51
Canada
Niraparib, MK4827, TSR-042, Dostarlimab
University Health Network, Toronto, Tesaro, Inc.
Endometrial Cancer
01/21
12/25
2020-004414-35: Improving public cancer care by implementing precision medicine in Norway

Not yet recruiting
2
2000
Europe
Alpelisib, Fulvestrant, imatinib, Hydroxyurea, bortezomib, capmatinib, Dactinomycin, tepotinib, dostarlimab, Capsule, hard, Injection, Infusion, Tablet, Capsule, Solution for injection, Powder and solvent for suspension for injection, Powder for solution for injection, Concentrate for solution for infusion, Alecensa, Erivedge, Phesgo, Rozlytrek, Tecentriq, Avastin, Zelboraf, Cotellic, Mekinist, Tafinlar, Alkeran, Piqray, Lynparza, Pemazyre, Tabrecta, Retsevmo, Tepmetko, Gavreto, Zejula
Oslo University Hospital, Oslo University Hospital
Patients with a biomarker indicating response to IMP can be included in IMPRESS-Norway. Patients with disease characteristics covered in present indications for the IMP are not eligible., Patients with a biomarker indicating response to the study drug can be included in the trial. Patients with disease characteristics covered in present indications for the study drug are not eligible., Diseases [C] - Cancer [C04]
 
 
NCT04409002: Niraparib + Dostarlimab + RT in Pancreatic Cancer

Completed
2
18
US
Niraparib, Zejula, Dostarlimab, Radiation
Massachusetts General Hospital, Tesaro, Inc.
Pancreatic Cancer, Metastatic Pancreatic Cancer
01/22
02/22
COHORT-A, NCT05751629: Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer

Completed
2
41
US
Dostarlimab, TSR-042, Bevacizumab, Avastin, Niraparib, ZEJULA
Tesaro, Inc.
Ovarian Neoplasm
04/22
04/22
PERLA, NCT04581824 / 2020-002327-11: Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Checkmark Presentation of data from PERLA trial for 1L non-squamous NSCLC at ESMO 2022
Dec 2022 - Dec 2022: Presentation of data from PERLA trial for 1L non-squamous NSCLC at ESMO 2022
Checkmark Updated results in comparison to Keytruda from PERLA study for treatment of patients with metastatic nonsquamous NSCLC
Nov 2022 - Nov 2022: Updated results in comparison to Keytruda from PERLA study for treatment of patients with metastatic nonsquamous NSCLC
Checkmark Data from PERLA study of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy for NSCLC
More
Active, not recruiting
2
243
Europe, US, RoW
Dostarlimab, Pembrolizumab, Chemotherapy
GlaxoSmithKline, GlaxoSmithKline
Lung Cancer, Non-Small Cell
08/22
10/25
2022-003289-18: Phase 2 Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Estudio de fase II de dostarlimab en pacientes con cáncer de recto dMMR/MSI-H localmente avanzado no tratado previamente

Ongoing
2
100
Europe
Dostarlimab, TSR-042, GSK4057190A, Concentrate for solution for infusion, Jemperli
GlaxoSmithKline Research & Development Limited, GlaxoSmithKline Research & Development Ltd
Untreated Stage II/III dMMR/MSI-H locally advanced rectal cancer cáncer de recto dMMR/MSI-H localmente avanzado en estadio II/III no tratado previamente, Rectal Cancer Cáncer de recto, Diseases [C] - Cancer [C04]
 
 
NADiR, NCT04837209: Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer

Recruiting
2
32
US
Niraparib, Zejula, Dostarlimab, TSR-042, WBP-285, Radiation therapy
Massachusetts General Hospital, Sibley Memorial Hospital, Duke University, University of Pennsylvania
Breast Cancer, Triple Negative Breast Cancer
04/25
12/29
PRIME, NCT04681469: Induction and Maintenance Treatment With PARP Inhibitor and Immunotherapy in HPV-negative HNSCC

Recruiting
2
49
Europe
Niraparib, Dostarlimab
Gruppo Oncologico del Nord-Ovest
Head and Neck Squamous Cell Carcinoma
06/23
06/28
STAR, NCT04068753: Niraparib in Combination With Dostarlimab in Patients With Recurrent or Progressive Cervix Cancer

Recruiting
2
66
US
Niraparib, dostarlimab
University of Oklahoma, Tesaro, Inc.
Recurrent Cervix Cancer, Progressive Cervix Cancer
07/25
07/27
MiST, NCT03654833: Mesothelioma Stratified Therapy () : A Multi-drug Phase II Trial in Malignant Mesothelioma

Active, not recruiting
2
186
Europe
Rucaparib, CO-338, Abemaciclib, LY2835219, pembrolizumab & bemcentinib, Keytruda; BGB324, Atezolizumab & Bevacizumab, MPDL3280A; Avastin, Dostarlimab and Niraparib, Zejula
University of Leicester, British Lung Foundation, Clovis Oncology, Inc., Eli Lilly and Company, Merck Sharp & Dohme LLC, BerGenBio ASA, Roche Pharma AG, University Hospitals, Leicester, The Christie NHS Foundation Trust, GlaxoSmithKline
Mesothelioma, Malignant
10/23
10/23
NIRADO, NCT04779151: Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab

Suspended
2
51
Europe
Dostarlimab, Niraparib
Gustave Roussy, Cancer Campus, Grand Paris
Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer, Biliary Tract Cancer, Platinum-sensitive Urothelial Bladder Cancer, Clear Cell Renal Cell Carcinoma, Pancreatic Ductal Adenocarcinoma
12/24
12/27
NCT06238635: Dostarlimab and Cobolimab in Advanced Cervical Cancer

Recruiting
2
66
US
Dostarlimab, TSR-042, GSK4057190, C6420H9832N1680O2014S44, Cobolimab, TSR-022, GSK4069889A
Meghan Shea, GlaxoSmithKline
Cervical Cancer, Advanced Cervical Carcinoma, Metastatic Cervical Cancer, Metastatic Cervical Carcinoma, Recurrent Cervical Carcinoma
02/26
07/27
ACCeSs, NCT04274023: Study on TSR-042 in Advanced Clear Cell Sarcoma

Terminated
2
3
Europe
TSR-042
Italian Sarcoma Group, GlaxoSmithKline
Sarcoma, Clear Cell
01/24
01/24
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
RUBY-J, NCT06317311: A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Recruiting
2
36
Japan
Dostarlimab, Carboplatin, Paclitaxel
GlaxoSmithKline
Carcinoma
07/26
08/27
NCT04313504: Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Active, not recruiting
2
23
US
Niraparib, ZEJULA, Dostarlimab, TSR-042
Trisha Wise-Draper, GlaxoSmithKline
Head and Neck Cancer
06/24
06/27
SATELLITE, NCT06278857: Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Not yet recruiting
2
10
RoW
Dostarlimab-Gxly 50 MG/1 ML Intravenous Solution [JEMPERLI], JEMPERLI
Queensland Centre for Gynaecological Cancer, GlaxoSmithKline Research & Development Limited
Endometrial Cancer Stage I, Mmr Deficiency, Endometrioid Endometrial Adenocarcinoma, Immune-related Adverse Event
06/26
06/28
UNITO-001, NCT04940637: - Study in HRR/PDL1 Positive MPM/NSCLC

Recruiting
2
70
Europe
niraparib and dostarlimab, no other intervention
University of Turin, Italy
Lung Cancer, Mesothelioma
06/24
06/25
NCT06365970: Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Not yet recruiting
2
20
US
Niraparib, Zejula, Dostarlimab, Jemperli
Ibrahim Halil Sahin, GlaxoSmithKline
MMR-D/MSI-H Colorectal Cancers
07/26
07/27
NCT04584255: Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Recruiting
2
62
US
Niraparib, Zejula, Dostarlimab, TSR042
Dana-Farber Cancer Institute, Translational Breast Cancer Research Consortium, Johns Hopkins University, GlaxoSmithKline
Stage I Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Breast Cancer, HER2-negative Breast Cancer, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, Deleterious PALB2 Gene Mutation
07/25
07/29
DIDO, NCT04983745: Niraparib and Dostarlimab in HRD Solid Tumors

Recruiting
2
30
US
Combination drug
West Cancer Center
Homologous Recombination Deficient Solid Tumors
08/24
08/25
NCT04493060: Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1/2 and PALB2 Mutated Metastatic Pancreatic Cancer

Active, not recruiting
2
22
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Niraparib, MK-4827, MK4827
Mayo Clinic, National Cancer Institute (NCI)
Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
12/23
09/24
NCT03680508: TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer

Recruiting
2
42
US
TSR-022 and TSR-042, cobolimab, TIM-3 binding antibody, dostarlimab, PD-1 binding antibody
University of Hawaii, GlaxoSmithKline
Adult Primary Liver Cancer, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
10/24
10/25
NCT05126342: Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Not yet recruiting
2
100
NA
Niraparib, Zejula, Dostarlimab, TSR-042
AGO Research GmbH, GlaxoSmithKline
Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal Cancer
11/24
11/26
NCT05870761: Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma

Recruiting
2
35
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Dostarlimab, ANB011, Dostarlimab-gxly, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, Jemperli, TSR 042, TSR-042, TSR042, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Niraparib, MK-4827, MK4827
Casey Cosgrove
Recurrent Endometrial Serous Adenocarcinoma
12/24
12/24
Neo-MEL-T, NCT04139902: Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma

Recruiting
2
56
US
Dostarlimab (TSR-042) (singly), Dostarlimab, Dostarlimab (TSR-042) and TSR-022 (combination)
Diwakar Davar, Tesaro, Inc.
Melanoma Stage III, Melanoma Stage IV
09/25
04/29
NCT05565378 / 2021-005115-32: A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Recruiting
2
300
Europe, Japan, US, RoW
Pembrolizumab, Dostarlimab, Belrestotug, EOS884448, GSK4428859A, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Lung Cancer, Non-Small Cell
01/25
01/28
NCT04774419: Radiation and TSR-042 (Dostarlimab) in People With Endometrial Cancer After They Receive Surgery

Active, not recruiting
2
31
US
Intensity modulated radiation therapy (IMRT), Dostarlimab, TSR-042
Memorial Sloan Kettering Cancer Center, Tesaro, Inc.
Endometrial Cancer
02/25
02/25
NCT04701307: Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

Active, not recruiting
2
48
US
Dostarlimab, ANB011, Immunoglobulin G4, Anti-programmed Cell Death Protein 1 (PDCD1) (Humanized Clone ABT1 Gamma4-chain), Disulfide with Humanized Clone ABT1 Kappa-chain, Dimer, TSR 042, TSR-042, TSR042, Niraparib, MK-4827, MK4827
M.D. Anderson Cancer Center
Lung Small Cell Carcinoma, Neuroendocrine Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8
05/25
05/25
NCT05065021: Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Recruiting
2
40
Canada
Niraparib, ZEJULA, Dostarlimab, Bevacizumab, Paclitaxel
University Health Network, Toronto, GlaxoSmithKline
Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High Grade Serous Cancer, High Grade Endometrioid Cancer
06/25
06/25
NCT03739710 / 2018-001316-29: Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Recruiting
2
185
Europe, Canada, US, RoW
Docetaxel, Feladilimab, Ipilimumab, GSK4428859A, belrestotug, EOS884448, Dostarlimab, GSK6097608
GlaxoSmithKline, iTeos Belgium SA
Neoplasms
07/25
07/25
NCT05700721: Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Active Progressing Brain Metastases (STARLET)

Recruiting
2
120
US
Niraparib, MK-4827, Dostarlimab
M.D. Anderson Cancer Center
Brain Metastases
08/25
08/27
NCT05526989: Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Recruiting
2
25
US
Dostarlimab, Jemperli, Niraparib, Zejula
H. Lee Moffitt Cancer Center and Research Institute, GlaxoSmithKline
Penile Carcinoma
10/25
10/26
ATOMICC, NCT03833479 / 2018-002155-15: TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Active, not recruiting
2
132
Europe, RoW
No Further Treatment, TSR-042
Grupo Español de Investigación en Cáncer de Ovario, TESARO/GSK, Apices Soluciones S.L.
Cervical Cancer, Advanced Cancer
12/25
12/25
NAIO, NCT05239546: Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers

Recruiting
2
25
US
Dostarlimab, TSR-042
University of Iowa
Colon Cancer, dMMR Colorectal Cancer
04/26
12/30
AZUR-1, NCT05723562 / 2022-003289-18: A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Recruiting
2
150
Europe, Canada, Japan, US, RoW
Dostarlimab, JEMPERLI, dostarlimab-gxly, TSR-042, GSK4057190A
GlaxoSmithKline, GlaxoSmithKline Research & Development Ltd
Neoplasms, Rectal
11/26
10/29
NCT04165772: Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Recruiting
2
200
US
TSR-042 or Dostarlimab, Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT)
Memorial Sloan Kettering Cancer Center, Tesaro, Inc.
Rectal Adenocarcinoma, Clinical Stage: Stage II (T3-4, N-), Stage III (Any T, N+), Solid Tumor, Solid Tumor, Adult
11/26
11/26
NCT05405192: Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Withdrawn
2
24
US
Dostarlimab
University of Miami, GlaxoSmithKline
Gestational Trophoblastic Neoplasia
12/26
12/28
NCT06062420: Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Recruiting
2
360
Europe, Canada, Japan, US, RoW
Dostarlimab, Belrestotug, GSK6097608
GlaxoSmithKline, iTeos Therapeutics
Neoplasms, Head and Neck
09/25
08/27
DOVE, NCT06023862: A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: (APGOT-OV7/ ENGOT-ov80 Study)

Recruiting
2
198
RoW
Dostarlimab, Jemperli, Bevacizumab, Doxorubicin, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin
Yonsei University
Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms, Vulvar Cancer, Vagina Neoplasm, Clear Cell Carcinoma
08/27
12/29
PREDOSTAR, NCT05855811: PREventing Second Cancers With DOSTARlimab

Recruiting
2
400
Europe
Dostarlimab
Centre Leon Berard, GlaxoSmithKline
Recurrent Cancer, Primary Cancer, Second Cancer
07/28
03/29
DEWI, NCT06059495: Watch-and-Wait Approach With Dostarlimab in Localized dMMR/MSI-H Gastric Cancer: GERCOR Phase II Study

Recruiting
2
59
Europe
Dostarlimab, Jemperli
GERCOR - Multidisciplinary Oncology Cooperative Group
Adenocarcinoma - GEJ, Gastric Adenocarcinoma
09/28
09/28
I-SPY 2, NCT01042379: I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

Hourglass Jan 2023 - Dec 2023 : From P2 I-SPY 2 trial for invasive breast cancer
Checkmark Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Dec 2022 - Dec 2022: Presentation of data from I-SPY trial for HR+/HER2- and TNBC breast cancer at SABCS 2022
Checkmark Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
Nov 2018 - Nov 2018: Data from trial evaluating T-DM1+pertuzumab in the adjuvant setting
More
Recruiting
2
5000
US
Standard Therapy, Paclitaxel (Taxol); Doxorubicin (Adriamycin), AMG 386 with or without Trastuzumab, AMG 386 (Trebananib); (Trastuzumab) Herceptin, AMG 479 (Ganitumab) plus Metformin, Ganitumab, MK-2206 with or without Trastuzumab, (Trastuzumab) Herceptin, AMG 386 and Trastuzumab, AMG 386 (Trebananib); Trastuzumab (Herceptin), T-DM1 and Pertuzumab, T-DM1 (Trastuzumab emtansine); Pertuzumab (Perjeta), Pertuzumab and Trastuzumab, Pertuzumab (Perjeta); Trastuzumab (Herceptin), Ganetespib, ABT-888, Veliparib, Neratinib, PLX3397, Pembrolizumab - 4 cycle, Talazoparib plus Irinotecan, Patritumab and Trastuzumab, Pembrolizumab - 8 cycle, SGN-LIV1A, Durvalumab plus Olaparib, SD-101 + Pembrolizumab, Tucatinib plus trastuzumab and pertuzumab, Cemiplimab, Cemiplimab plus REGN3767, Trilaciclib with or without trastuzumab + pertuzumab, Trilaciclib (G1T28); Pertuzumab (Perjeta); Trastuzumab (Herceptin), SYD985 ([vic-]trastuzumab duocarmazine), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab, Oral Paclitaxel + Encequidar (Oraxol); Dostarlimab (TSR-042); Trastuzumab (Herceptin), Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab, Amcenestrant, SAR439859, Amcenestrant + Abemaciclib, Amcenestrant (SAR439859), Abemaciclib (Verzenio), Amcenestrant + Letrozole, Amcenestrant (SAR439859), Letrozole (Femara), ARX788, ARX788 + Cemiplimab, VV1 + Cemiplimab, VOYAGER V1™, VSV-IFNβ-NIS, Datopotamab deruxtecan, Dato-DXd, Datopotamab deruxtecan + Durvalumab, Zanidatamab, Lasofoxifene, Z-endoxifen, ARV-471, ARV-471 + Letrozole
QuantumLeap Healthcare Collaborative
Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
12/30
12/31
IMPRESS-Norway, NCT04817956: Improving Public Cancer Care by Implementing Precision Medicine in Norway

Recruiting
2
3000
Europe
Atezolizumab, Atezolizumab combined with bevacizumab, Phesgo (trastuzumab og pertuzumab), Alectinib, vismodegib, entrectinib, Vemurafenib and cobemitinib, Niraparib, Dostarlimab, Ceritinib
Oslo University Hospital, Haukeland University Hospital, St. Olavs Hospital, University Hospital of North Norway, University Hospital, Akershus, Vestre Viken Hospital Trust, Hospital of Southern Norway Trust, Ostfold Hospital Trust, The Hospital of Vestfold, Helse Stavanger HF, Nordlandssykehuset HF, Sykehuset Innlandet HF, Helse Forde, Helse Fonna HF, Helse Nord-Trøndelag HF, Helse Møre og Romsdal HF, Sykehuset Telemark, Lovisenberg Diakonale Hospital
Cancer Metastatic
03/40
04/45
OPAL, NCT03574779: A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Hourglass Oct 2019 - Dec 2019 : Proof-of-concept data from OPAL trial in combination with dostarlimab and Avastin for 2L+ PROC ovarian cancer
Recruiting
1b/2
125
Europe, Canada, US
Niraparib, ZEJULA, TSR-042, Bevacizumab, Avastin, Carboplatin, Paclitaxel
Tesaro, Inc.
Ovarian Neoplasms
08/24
03/26
2021-001329-29: A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participants with advanced solid tumors

Not yet recruiting
1/2
276
Europe
EOS-448, Inupadenant, Pembrolizumab, Inupadenant hydrochloride, Dostarlimab, EOS884448, EOS100850, L01XC18, EOS100850 HCl, Solution for infusion, Capsule, Keytruda® (pembrolizumab), Dostarlimab
iTeos Belgium SA, iTeos Belgium SA
Advanced solid tumors, Advanced solid Tumors, Diseases [C] - Cancer [C04]
 
 
2023-000183-65: Niraparib and Dostarlimab plus (Chemo)RadIotherapy in head and Neck squamous cell carcinoma niraparib y dostarlimab más (quimio)radioterapia en carcinoma de células escamosas de cabeza y cuello

Not yet recruiting
1/2
34
Europe
Niraparib, Dostarlimab, Tablet, Concentrate for solution for infusion
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello (TTCC), GSK
Locally-Advanced head and Neck squamous cell carcinoma Carcinoma de células escamosas de cabeza y cuello localmente avanzado, Head and Neck squamous cell carcinoma Carcinoma de células escamosas de cabeza y cuello, Diseases [C] - Cancer [C04]
 
 
TIG-006, NCT05060432: Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Active, not recruiting
1/2
153
Europe, US
EOS-448, EOS884448, GSK4428859, belrestotug, pembrolizumab, inupadenant, EOS100850, Dostarlimab, SOC chemotherapies
iTeos Belgium SA, GlaxoSmithKline, iTeos Therapeutics
Advanced Cancer, Lung Cancer, Head and Neck Cancer, Melanoma
07/24
07/25
LiDer, NCT06385548: Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 -

Not yet recruiting
1/2
15
NA
Lurbinectedin, Dostarlimab
Vall d'Hebron Institute of Oncology
Endometrial Cancer
05/24
04/26
NCT06405230: Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Patient-derived Organoids and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Not yet recruiting
1/2
40
Europe
Pembrolizumab, Dostarlimab, Pemetrexed+ (carboplatin or cisplatin)
GlaxoSmithKline
Lung Cancer, Non-Small Cell
01/27
07/27
NCT05559879: Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

Recruiting
1/2
37
US
Cabo + Dostarlimab
University of Alabama at Birmingham
Gynecologic Cancer, Carcinoma, Uterine Cancer, Endometrial Cancer
12/24
12/25
TOPAZ, NCT04926324: A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Recruiting
1/2
38
US
Niraparib, Zejula, Dostarlimab, Jemperli, Short course radiation, IMRT, VMAT
Joseph Caster, Ph.D., M.D., GlaxoSmithKline
Rectal Neoplasms, Rectal Neoplasm Malignant
12/24
12/26
NCT06065462: Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Recruiting
1/2
21
US
Dostarlimab, LB-100
M.D. Anderson Cancer Center, GSK Pharma, Lixte
Ovarian Clear Cell Carcinoma
01/26
01/26
DREAMM 5, NCT04126200 / 2019-001138-32: Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Hourglass Jul 2021 - Dec 2021 : From DREAMM-5 trial in combination with nirogacestat for r/r multiple myeloma
Hourglass Feb 2020 - Mar 2020 : Initiation of P1b sub-study of P2 DREAMM-5 trial in combination with nirogacestat for relapsed/refractory multiple myeloma
Checkmark From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Nov 2019 - Nov 2019: From DREAMM 5 trial in R/R multiple myeloma patients at ASH 2019
Checkmark Initiation of DREAMM-5 trial in r/r multiple myeloma
More
Recruiting
1/2
464
Europe, Canada, Japan, US, RoW
Belantamab mafodotin, GSK3174998, Feladilimab, Nirogacestat, Dostarlimab, Isatuximab, Lenalidomide, Dexamethasone, Pomalidomide
GlaxoSmithKline
Multiple Myeloma
02/26
02/29
RADIAN, NCT05784012: Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Recruiting
1/2
34
Europe
Dostarlimab, Niraparib, cisplatin plus radiotherapy
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello, GlaxoSmithKline, MFAR
Head and Neck Squamous Cell Carcinoma
09/27
03/29

Download Options